Selective cytopheretic inhibitory device with regional citrate anticoagulation and portable sorbent dialysis.
Selective cytopheretic inhibitory device (SCD) therapy is an immunomodulatory treatment provided by a synthetic biomimetic membrane in an extracorporeal circuit, which has shown promise in preclinical large animal models of severe sepsis as well as in clinical trials treating patients with acute kidney injury and multiple organ failure. During SCD therapy, citrate is administered to lower ionized calcium levels in blood for anticoagulation and inhibition of leukocyte activation. Historically, citrate has been known to interfere with sorbent dialysis, therefore, posing a potential issue for the use of SCD therapy with a portable dialysis system. This sorbent dialysis SCD (sorbent SCD) would be well suited for battlefield and natural disaster applications where the water supply for standard dialysis is limited, and the types of injuries in those settings would benefit from SCD therapy. In order to explore the compatibility of sorbent and SCD technologies, a uremic porcine model was tested with the Allient sorbent dialysis system (Renal Solutions Incorporated, Fresenius Medical Care, Warrendale, PA, USA) and concurrent SCD therapy with regional citrate anticoagulation. The hypothesis to be assessed was whether the citrate load required by the SCD could be metabolized prior to recirculation from systemic blood back into the therapeutic circuit. Despite the fact that the sorbent SCD maintained urea clearance without any adverse hematologic events, citrate load for SCD therapy caused an interaction with the sorbent column resulting in elevated, potentially toxic aluminum levels in dialysate and in systemic blood. Alternative strategies to implement sorbent-SCD therapy will be required, including development of alternate urease-sorbent column binding chemistry or further changes to the sorbent-SCD therapeutic circuit along with determining the minimum citrate concentration required for efficacious SCD treatment.
Innovative BioTherapies, Inc., Ann Arbor, MI, USA.
Christopher J
CJ
Pino
Amin
A
Farokhrani
Liandi
L
Lou
Peter L
PL
Smith
Kimberly
K
Johnston
Deborah A
DA
Buffington
H David
HD
Humes
D000818:Animals; D000925:Anticoagulants / Q000008:administration & dosage*; D015415:Biomarkers / Q000097:blood; D040761:Biomimetic Materials; D019343:Citric Acid / Q000008:administration & dosage*; D004195:Disease Models, Animal; D005112:Extracorporeal Circulation / Q000295:instrumentation*; D007167:Immunotherapy / Q000295:instrumentation* / Q000379:methods; D007937:Leukapheresis / Q000295:instrumentation* / Q000379:methods; D007962:Leukocytes / Q000276:immunology; D008422:Materials Testing; D008567:Membranes, Artificial; D006435:Renal Dialysis / Q000295:instrumentation* / Q000379:methods; D013552:Swine; D013997:Time Factors; D014511:Uremia / Q000097:blood / Q000276:immunology / Q000628:therapy*
D000925:Anticoagulants; D015415:Biomarkers; D008567:Membranes, Artificial; D019343:Citric Acid